Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

Publication | Open Access

DOI Full Paper Access

Citations

References

2014

Year

P. Schöffski, Benjamin Besse, Thomas Gauler, Maja J.A. de Jonge, Giovanni Scambia, Armando Santoro, C. Davite, M.G. Jannuzzo, Anna Petroccione, J.-P. Delord

Annals of Oncology

Non-small-cell Lung CancerBiweekly I.vMedicineCancer ManagementPharmacologyBreast CancerAnti-cancer AgentCancer TreatmentMetastatic BreastOncologyRadiation OncologyLung Cancer